Dr Reddys Laboratories Stock Today
| RDY Stock | USD 70.92 0.57 0.80% |
Performance2 of 100
| Odds Of DistressLess than 6
|
Dr Reddys is trading at 70.92 as of the 25th of April 2024; that is -0.8 percent decrease since the beginning of the trading day. The stock's open price was 71.49. Dr Reddys has only a 6 % chance of going through financial distress over the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Dr Reddys Laboratories are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of May 2022 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of April 2001 | Category Healthcare | Classification Health Care |
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 166.53 M outstanding shares of which 625.76 K shares are at this time shorted by investors with about 3.51 days to cover. More on Dr Reddys Laboratories
Moving against RDY Stock
| 0.45 | ACB | Aurora Cannabis Trending | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
RDY Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Dr Reddys' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Dr Reddys or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | MARC KIKUCHI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SPASX All Technology, ARCA Pharmaceutical, Healthcare, Obamacare, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Dr Reddys report their recommendations after researching Dr Reddys' financial statements, talking to executives and customers, or listening in on Dr Reddys' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dr Reddys Laboratories. The RDY consensus assessment is calculated by taking the average forecast from all of the analysts covering Dr Reddys. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Dr Reddys' liquidity, profitability, solvency, and operating efficiency, Dr Reddys Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Dr Reddys Laboratories is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr Reddys' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Dr Reddys' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dr Reddys' financial leverage. It provides some insight into what part of Dr Reddys' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA. It is located in 8-2-337, Road No. 3, Hyderabad, India, 500034 and employs 25,863 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 11.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dr Reddys's market, we take the total number of its shares issued and multiply it by Dr Reddys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Dr Reddys Laboratories runs under Pharmaceuticals sector within Health Care industry. The entity has 166.53 M outstanding shares of which 625.76 K shares are at this time shorted by investors with about 3.51 days to cover.
Dr Reddys Laboratories has about 2.93 B in cash with 58.87 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 208.58.
Check Dr Reddys Probability Of Bankruptcy
Ownership AllocationDr Reddys Laboratories secures a total of 166.53 Million outstanding shares. About 85.0 % of Dr Reddys outstanding shares are held by general public with 15.02 (percent) by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check RDY Ownership Details
RDY Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Dr Reddys jumping above the current price in 90 days from now is about 85.48%. The Dr Reddys Laboratories probability density function shows the probability of Dr Reddys stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Dr Reddys Laboratories has a beta of -0.0111 indicating as returns on the benchmark increase, returns on holding Dr Reddys are expected to decrease at a much lower rate. During a bear market, however, Dr Reddys Laboratories is likely to outperform the market. Additionally, dr Reddys Laboratories has an alpha of 0.0757, implying that it can generate a 0.0757 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Dr Reddys to move above the current price in 90 days from now is about 85.48 (This Dr Reddys Laboratories probability density function shows the probability of RDY Stock to fall within a particular range of prices over 90 days) .
RDY Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2023-12-31 | 562.6 K | |
| Gqg Partners Llc | 2023-12-31 | 437 K | |
| Lazard Asset Management Llc | 2023-12-31 | 347.1 K | |
| Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 329.1 K | |
| Schroder Investment Management Group | 2023-12-31 | 266.7 K | |
| Mondrian Investment Partners Ltd | 2023-12-31 | 219 K | |
| Acadian Asset Management Llc | 2023-12-31 | 211.3 K | |
| Fisher Asset Management, Llc | 2023-12-31 | 205.3 K | |
| Ameriprise Financial Inc | 2023-12-31 | 198.2 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 3.7 M | |
| Blackrock Inc | 2023-12-31 | 3 M |
Dr Reddys Historical Income Statement
Dr Reddys Laboratories Income Statement is one of the three primary financial statements used for reporting RDY's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dr Reddys Laboratories revenue and expense. Dr Reddys Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 116.3 B in 2024, whereas Cost Of Revenue is likely to drop slightly above 44.3 B in 2024. View More FundamentalsRDY Stock Against Markets
Picking the right benchmark for Dr Reddys stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dr Reddys stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dr Reddys is critical whether you are bullish or bearish towards Dr Reddys Laboratories at a given time. Please also check how Dr Reddys' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Dr Reddys without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Dr Reddys Corporate Directors
Dr Reddys corporate directors refer to members of a Dr Reddys board of directors. The board of directors generally takes responsibility for the Dr Reddys' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Dr Reddys' board members must vote for the resolution. The Dr Reddys board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Leo Puri | Non-Executive Independent Director | Profile | |
| Ravi Bhoothalingam | Non-Executive Independent Director | Profile | |
| Prasad Menon | Lead Non-Executive Independent Director | Profile | |
| Shikha Sharma | Non-Executive Independent Director | Profile |
How to buy RDY Stock?
Before investing in Dr Reddys, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Dr Reddys. To buy Dr Reddys stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Dr Reddys. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Dr Reddys stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Dr Reddys Laboratories stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Dr Reddys Laboratories stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Dr Reddys Laboratories, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy RDY Stock please use our How to Invest in Dr Reddys guide.
Already Invested in Dr Reddys Laboratories?
The danger of trading Dr Reddys Laboratories is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Dr Reddys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Dr Reddys. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Dr Reddys Laboratories is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.